Exchange: NASDAQ·Updated 07:57 PM EDT
MRNA logo

MRNAModerna Inc

$58.07
$1.59
(2.67%)
Today
Closed $58.07
$0.02
(0.03%)
After Hours
EarningsJul 31
Mkt Cap$23.67B
Vol3.78M
News
all
press releases
Should You Buy Moderna Stock Hand Over Fist Before Aug. 5?
Key PointsModerna is racing towards an important approval...
Nasdaq News: Markets
More News
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?
Key PointsModerna is known as a coronavirus vaccine giant, but it's progressively becoming a multi-product company...
Nasdaq News: Markets
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Moderna (MRNA) closed at $59.49, indicating a -3.77% shift from the previous trading day.
Zacks
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Zacks
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.
Stocktwits
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Zacks
MRNA Stock Eyes Worst Week In 11 Months After June Surge — What’s Ahead?
The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May.
Stocktwits
RFK Jr. Plans To Create A List Of Injuries Caused By COVID-19 Vaccines
RFK Jr. Plans To Create A List Of Injuries Caused By COVID-19 Vaccines Authored by Zachary Stieber via The Epoch Times, Health officials are proposing a plan to clarify which COVID-19 vaccine side effects would be eligible for government financial compensation, according to a new...
Zero Hedge
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.
Zacks
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
Arbutus expects to receive around $179 million from Moderna.
Stocktwits
<
1
2
...
>

Advertisement|Remove ads.